Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 7/20 | 0.50 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 4/20 | 0.40 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.40 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.39 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.39 |
| ▸ | RET known ✓ | P07949 | 2/20 | 0.39 |
| ▸ | CHRM2 known ✓ | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 known ✓ | P08173 | 2/20 | 0.39 |
| ▸ | ADRB1 known ✓ | P08588 | 2/20 | 0.39 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.39 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.39 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.39 |
| ▸ | DRD2 known ✓ | P14416 | 2/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.39 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.39 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.39 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6969176 | 0.91 | HRH1 (0.48) | HRH1SIGMAR1SLC6A2LMNACYP3A4 | |
| SCHEMBL5501785 | 0.89 | HRH1 (0.48) | HRH1SIGMAR1SLC6A2LMNACYP3A4 | |
| Hydrochloric Acid SCHEMBL8194748 | 0.89 | ALDH1A1 (0.52) | HRH1LMNAALDH1A1SLC6A1CYP1A2 | |
| SCHEMBL6957956 | 0.87 | KDM4E (0.47) | HRH1LMNAMAPTKMT2AKDM4E | |
| SCHEMBL7605820 | 0.87 | SLC6A1 (0.52) | HRH1LMNAALDH1A1SLC6A1CYP1A2 | |
| SCHEMBL6959262 | 0.83 | HRH1 (0.48) | HRH1SIGMAR1CHRM3TBXA2R | |
| SCHEMBL6967438 | 0.83 | HRH1 (0.45) | HRH1SIGMAR1DRD2HTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6956807 | 0.81 | KDM4E (0.53) | LMNAMEN1MAPTKMT2AKDM4E | |
| SCHEMBL7604557 | 0.80 | HRH1 (0.46) | HRH1SIGMAR1CHRM1ADRA1DADRA1A | |
| Hydrochloric Acid SCHEMBL6965368 | 0.79 | HRH1 (0.47) | HRH1SLC6A2LMNACYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613791-B1 | Treating migraine, neurogenic inflammation, rheumatoid arthritis or insulin resistance | NOVO NORDISK A/S (DK) | 2003-09-02 | — | — | US | disclosed |
| EP-0820451-B1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK AS (DK) | 2003-01-15 | — | — | EP | disclosed |
| US-6239148-B1 | TREATMENT OF PAINFUL, HYPERALGESIC AND/OR INFLAMMATORY CONDITIONS IN WHICH C-FIBERS PLAY A ROLE BY ELICITING NEUROGENIC PAIN, INSULIN RESISTANCE IN DIABETES MELLITUS OR AGING, INHIBIT INSULIN ANTAGONIZING PEPTIDE, | NOVO NORDISK A/S (DK) | 2001-05-29 | — | — | US | disclosed |
| US-6166009-A | N-substituted azaheterocyclic carboxylic acids and esters thereof | NOVO NORDISK A/S (DK) | 2000-12-26 | — | — | US | disclosed |
| US-6110913-A | ANTIINFLAMMATORY AGENTS, ANALGESICS | NOVO NORDISK A/S (DK) | 2000-08-29 | — | — | US | disclosed |
| EP-0820451-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996031498-A1 | NOVEL HETEROCYCLIC COMPOUNDS | NOVO NORDISK A/S (DK) | 1996-10-10 | — | — | WO | disclosed |